Cited by 758Pluripotent Stem Cells ResearchOrgan and Tissue Transplantation ResearchMesenchymal stem cell research

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Hypoimmunogenic derivatives of induced pluripotent stem cells evade immune rejection in fully immunocompetent allogeneic recipients

Open access

Deuse, Tobias, Hu, Xiaomeng, Gravina, Alessia, Wang, Dong, Tediashvili, Grigol, De, Chandrav, Thayer, William O., Wahl, Angela, Garcia, J. Victor, Reichenspurner, Hermann, Davis, Mark M., Lanier, Lewis L., Schrepfer, Sonja·2019·Nature Biotechnology

DOI 10.1038/s41587-019-0016-3PMC PMC6419516

Open this paper in CoChat — free account

Abstract

Autologous induced pluripotent stem cells (iPSCs) constitute an unlimited cell source for patient-specific cell-based organ repair strategies. However, their generation and subsequent differentiation into specific cells or tissues entail cell line-specific manufacturing challenges and form a lengthy process that precludes acute treatment modalities. These shortcomings could be overcome by using prefabricated allogeneic cell or tissue products, but the vigorous immune response against histo-incompatible cells has prevented the successful implementation of this approach. Here we show that both mouse and human iPSCs lose their immunogenicity when major histocompatibility complex (MHC) class I and II genes are inactivated and CD47 is over-expressed. These hypoimmunogenic iPSCs retain their pluripotent stem cell potential and differentiation capacity. Endothelial cells, smooth muscle cells, and cardiomyocytes derived from hypoimmunogenic mouse or human iPSCs reliably evade immune rejection in fully MHC-mismatched allogeneic recipients and survive long-term without the use of immunosuppression. These findings suggest that hypoimmunogenic cell grafts can be engineered for universal transplantation.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/s41587-019-0016-3

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis
Jaiswal, S., Jamieson, C. H. M., Pang, W. W., Park, C. Y., Chao, M. P., Majeti, R., Traver, D. J., van Rooijen, N., & Weissman, I. L. (2009) · Cell · doi:10.1016/j.cell.2009.05.046 · Cited by 1,578
Humanized mice in translational biomedical research
Shultz, L. D., Ishikawa, F., & Greiner, D. L. (2007) · Nature reviews. Immunology · doi:10.1038/nri2017 · Cited by 1,393
Humanized mice in translational biomedical research
Shultz, L. (2007) · The Mouseion at the JAXlibrary (Jackson Laboratory) · Cited by 1,036
Allogeneic transplantation of iPS cell-derived cardiomyocytes regenerates primate hearts
Shiba, Y., Gomibuchi, T., Seto, T., Wada, Y., Ichimura, H., Tanaka, Y., Ogasawara, T., Okada, K., Shiba, N., Sakamoto, K., et al. (2016) · Nature · doi:10.1038/nature19815 · Cited by 840
Humanized mice mount specific adaptive and innate immune responses to EBV and TSST-1
Melkus, M. W., Estes, J. D., Padgett‐Thomas, A., Gatlin, J., Denton, P. W., Othieno, F. A., Wege, A. K., Haase, A. T., & Garcia, J. V. (2006) · Nature Medicine · doi:10.1038/nm1431 · Cited by 653
Self-citation
HLA-E-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cells
Gornalusse, G. G., Hirata, R. K., Funk, S. E., Riolobos, L., Lopes, V. S., Manske, G., Prunkard, D., Colunga, A. G., Hanafi, L.-A., Clegg, D. O., et al. (2017) · Nature Biotechnology · doi:10.1038/nbt.3860 · Cited by 639
Fetomaternal immune cross-talk and its consequences for maternal and offspring's health
Arck, P., & Hecher, K. (2013) · Nature Medicine · doi:10.1038/nm.3160 · Cited by 609
AML xenograft efficiency is significantly improved in NOD/SCID-IL2RG mice constitutively expressing human SCF, GM-CSF and IL-3
Wunderlich, M., Chou, F.-S., Link, K. A., Mizukawa, B., Perry, R. L., Carroll, M., & Mulloy, J. C. (2010) · Leukemia · doi:10.1038/leu.2010.158 · Cited by 415
Class II transactivator (CIITA) is sufficient for the inducible expression of major histocompatibility complex class II genes
Chang, C., Fontes, J., Peterlin, M., & Flavell, R. (1994) · Journal of Experimental Medicine · doi:10.1084/jem.180.4.1367 · Cited by 352
Meta-Analysis of Cell-based CaRdiac stUdiEs (ACCRUE) in Patients With Acute Myocardial Infarction Based on Individual Patient Data
Gyöngyösi, M., Wojakowski, W., Lemarchand, P., Lunde, K., Tendera, M., Bartunek, J., Marbán, E., Aßmus, B., Henry, T. D., Traverse, J. H., et al. (2015) · Circulation Research · doi:10.1161/circresaha.116.304346 · Cited by 313

Show all 31 references

Sorted by citations

Items 201–300 of 758

MHC Class I Enables MSCs to Evade NK-Cell–Mediated Cytotoxicity and Exert Immunosuppressive Activity
Oh, J. Y., Kim, H., Lee, H. J., Lee, K., Barreda, H., Kim, H. J., Shin, E., Bae, E., Kaur, G., Zhang, Y., et al. (2022) · Stem Cells · doi:10.1093/stmcls/sxac043 · Cited by 32
Taking T-Cell Oncotherapy Off-the-Shelf
Mo, F., Mamonkin, M., Brenner, M. K., & Heslop, H. E. (2021) · Trends in Immunology · doi:10.1016/j.it.2021.01.004 · Cited by 31
Innovations in bio-engineering and cell-based approaches to address immunological challenges in islet transplantation
Ho, B. X., Teo, A. K. K., & Ng, N. H. J. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1375177 · Cited by 32
Updated perspectives on vascular cell specification and pluripotent stem cell-derived vascular organoids for studying vasculopathies
Liu, C., Niu, K., & Xiao, Q. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvaa313 · Cited by 31
Cell‐Based Therapy for Canavan Disease Using Human iPSC‐Derived NPCs and OPCs
Feng, L., Chao, J., Tian, E., Li, L., Ye, P., Zhang, M., Chen, X., Cui, Q., Sun, G., Zhou, T., et al. (2020) · Advanced Science · doi:10.1002/advs.202002155 · Cited by 30
Corneal epithelial differentiation of human pluripotent stem cells generates ABCB5+ and ∆Np63α+ cells with limbal cell characteristics and high wound healing capacity
Vattulainen, M., Ilmarinen, T., Viheriälä, T., Jokinen, V., & Skottman, H. (2021) · Stem Cell Research & Therapy · doi:10.1186/s13287-021-02673-3 · Cited by 31
Update on islet cell transplantation
Verhoeff, K., Marfil-Garza, B. A., & Shapiro, A. M. J. (2021) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0000000000000891 · Cited by 29
Synthetic immune checkpoint engagers protect HLA-deficient iPSCs and derivatives from innate immune cell cytotoxicity
Gravina, A., Tediashvili, G., Zheng, Y., Iwabuchi, K. A., Peyrot, S. M., Roodsari, S. Z., Gargiulo, L., Kaneko, S., Osawa, M., Schrepfer, S., et al. (2023) · Cell stem cell · doi:10.1016/j.stem.2023.10.003 · Cited by 30
Self-citation
Encapsulation and immune protection for type 1 diabetes cell therapy
Kioulaphides, S., & Garcı́a, A. J. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115205 · Cited by 37
Generation of hypoimmunogenic universal iPS cells through HLA-type gene knockout
Kim, J., Nam, Y., Jeon, D., Choi, Y.-J., Choi, S., Hong, C. P., Kim, S., Jung, H., Park, N., Sohn, Y., et al. (2025) · Experimental & Molecular Medicine · doi:10.1038/s12276-025-01422-3 · Cited by 36
Pluripotent Stem Cell-Derived Cardiomyocyte Transplantation for Heart Disease Treatment
Kadota, S., & Shiba, Y. (2019) · Current Cardiology Reports · doi:10.1007/s11886-019-1171-3 · Cited by 30
Challenges and perspectives of tendon-derived cell therapy for tendinopathy: from bench to bedside
Chen, Z., Chen, P., Zheng, M., Gao, J., Liu, D., Wang, P. A., Zheng, Q., Leys, T., Tai, A. C. P., & Zheng, M. (2022) · Stem Cell Research & Therapy · doi:10.1186/s13287-022-03113-6 · Cited by 34
Induced Pluripotent Stem Cells
Fakoya, A. O. J., Omole, A. E., Satyadev, N., & Haider, K. H. (2022) · Springer eBooks · doi:10.1007/978-981-16-6016-0_40-1 · Cited by 29
Engineering human pluripotent stem cell lines to evade xenogeneic transplantation barriers
Pizzato, H. A., Alonso‐Guallart, P., Woods, J., Jóhannesson, B., Connelly, J. P., Fehniger, T. A., Atkinson, J. P., Pruett‐Miller, S. M., Monsma, F. J., & Bhattacharya, D. (2024) · Stem Cell Reports · doi:10.1016/j.stemcr.2023.12.003 · Cited by 28
Human iPSC-derived macrophages for efficient Staphylococcus aureus clearance in a murine pulmonary infection model
Hashtchin, A. R., Fehlhaber, B., Hetzel, M., Manstein, F., Stalp, J. L., Glage, S., Abeln, M., Zweigerdt, R., Munder, A., Viemann, D., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021004853 · Cited by 29
Advances in Allogeneic Cancer Cell Therapy and Future Perspectives on “Off-the-Shelf” T Cell Therapy Using iPSC Technology and Gene Editing
Furukawa, Y., Hamano, Y., Shirane, S., Kinoshita, S., Azusawa, Y., Ando, J., Nakauchi, H., & Ando, M. (2022) · Cells · doi:10.3390/cells11020269 · Cited by 29
A risk-based approach for cell line development, manufacturing and characterization of genetically engineered, induced pluripotent stem cell–derived allogeneic cell therapies
Dashnau, J. L., Xue, Q., Nelson, M., Law, E., Cao, L., & Hei, D. J. (2022) · Cytotherapy · doi:10.1016/j.jcyt.2022.08.001 · Cited by 30
Myocardial regeneration protocols towards the routine clinical scenario: An unseemly path from bench to bedside
Salerno, N., Salerno, L., Marino, F., Scalise, M., Chiefalo, A., Panuccio, G., Angelis, A. D., Cianflone, E., Urbanek, K., & Torella, D. (2022) · EClinicalMedicine · doi:10.1016/j.eclinm.2022.101530 · Cited by 28
Universal cell donor lines: A review of the current research
Simpson, A., Hewitt, A. W., & Fairfax, K. A. (2023) · Stem Cell Reports · doi:10.1016/j.stemcr.2023.09.010 · Cited by 30
Challenges of CRISPR/Cas-Based Cell Therapy for Type 1 Diabetes: How Not to Engineer a “Trojan Horse”
Karpov, D. S., Sosnovtseva, A. O., Pylina, S. V., Bastrich, A., Petrova, D. A., Kovalev, M. A., Shuvalova, A. I., Константиновна, Е. А., & Mokrysheva, N. G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242417320 · Cited by 30
Applications of CRISPR technologies in transplantation
Kuscu, C., Kuscu, C., Bajwa, A., Eason, J. D., Maluf, D. G., & Mas, V. R. (2020) · American Journal of Transplantation · doi:10.1111/ajt.16095 · Cited by 28
Human pluripotent stem cell-derived eosinophils reveal potent cytotoxicity against solid tumors
Lai, W., Xie, H., Liu, Y., Zheng, F., Zhang, Y., Lei, Q., Lv, L., Dong, J., Song, J., Gao, X. C., et al. (2021) · Stem Cell Reports · doi:10.1016/j.stemcr.2021.06.005 · Cited by 28
Transplantation of Human Induced Pluripotent Stem Cell-Derived Neural Progenitor Cells Promotes Forelimb Functional Recovery after Cervical Spinal Cord Injury
Zheng, Y., Gallegos, C. M., Xue, H., Li, S., Kim, D., Zhou, H., Xia, X., Liu, Y., & Cao, Q. (2022) · Cells · doi:10.3390/cells11172765 · Cited by 31
Induction of long-term allogeneic cell acceptance and formation of immune privileged tissue in immunocompetent hostsPreprint
Harding, J. S., Nagy, K. V., Shutova, M. V., Yang, H., Tang, J. K., Massumi, M., Izaidfar, M., Izadifar, Z., Zhang, P., Li, C., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/716571 · Cited by 30
T-Cell Mediated Immune Rejection of Beta-2-Microglobulin Knockout Induced Pluripotent Stem Cell-Derived Kidney Organoids
Gaykema, L. H., van Nieuwland, R. Y., Lievers, E., Moerkerk, W. B. J., de Klerk, J. A., Dumas, S. J., Kers, J., Zaldumbide, A., van den Berg, C. W., & Rabelink, T. J. (2023) · Stem Cells Translational Medicine · doi:10.1093/stcltm/szad069 · Cited by 28
Synthetic transcription factor engineering for cell and gene therapy
Bhatt, B., García-Díaz, P., & Wink, G. (2023) · Trends in biotechnology · doi:10.1016/j.tibtech.2023.09.010 · Cited by 28
HIV immune evasin Nef enhances allogeneic CAR T cell potency
Perica, K., Kotchetkov, I. S., Mansilla‐Soto, J., Ehrich, F. D., Herrera, K., Shi, Y., Dobrin, A., Gönen, M., & Sadelain, M. (2025) · Nature · doi:10.1038/s41586-025-08657-0 · Cited by 29
T Lymphocyte Development and Activation in Humanized Mouse Model
Lee, J. Y., Han, A., & Lee, D. R. (2019) · Development & Reproduction · doi:10.12717/dr.2019.23.2.079 · Cited by 29
Hematopoietic Cells from Pluripotent Stem Cells: Hope and Promise for the Treatment of Inherited Blood Disorders
Rao, I., Crisafulli, L., Paulis, M., & Ficara, F. (2022) · Cells · doi:10.3390/cells11030557 · Cited by 27
Engineering stem cell therapeutics for cardiac repair
Fang, J., Li, J. J., Zhong, X., Zhou, Y., Lee, R. J., Cheng, K., & Li, S. (2022) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2022.06.013 · Cited by 27
Stem Cell Therapy for Repair of the Injured Brain: Five Principles
Rust, R., & Tackenberg, C. (2022) · The Neuroscientist · doi:10.1177/10738584221110100 · Cited by 24
Genetic engineering strategies to enhance antitumor reactivity and reduce alloreactivity for allogeneic cell-based cancer therapy
Chen, Y., Zhu, Y., Kramer, A. B., Fang, Y., Wilson, M., Li, Y.-R., & Yang, L. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1135468 · Cited by 26
Fully biologic endothelialized-tissue-engineered vascular conduits provide antithrombotic function and graft patency
Park, J., Riaz, M., Qin, L., Zhang, W., Batty, L. D., Fooladi, S., Kural, M. H., Li, X., Luo, H., Xu, Z., et al. (2024) · Cell stem cell · doi:10.1016/j.stem.2024.11.006 · Cited by 26
Engineered human pluripotent stem cell-derived natural killer cells: the next frontier for cancer immunotherapy
Huang, Z., & Kaufman, D. S. (2019) · Blood Science · doi:10.1097/bs9.0000000000000023 · Cited by 26
Human pluripotent stem cells: A toolbox to understand and treat retinal degeneration
Morizur, L., Herardot, E., Monville, C., & M’Barek, K. B. (2020) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2020.103523 · Cited by 29
Study of immune‐tolerized cell lines and extracellular vesicles inductive environment promoting continuous expression and secretion of HLA‐G from semiallograft immune tolerance during pregnancy
Cho, K., Kook, H., Kang, S., & Lee, J. (2020) · Journal of Extracellular Vesicles · doi:10.1080/20013078.2020.1795364 · Cited by 26
Small Extracellular Vesicles Derived from Induced Pluripotent Stem Cells in the Treatment of Myocardial Injury
Meng, W., & Guo, H.-D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054577 · Cited by 26
Strategies for the vascular patterning of engineered tissues for organ repair
Janson, K. D., Parkhideh, S., Swain, J. W. R., Weaver, J. D., Hartgerink, J. D., & Omid Veiseh, A. (2025) · Nature Biomedical Engineering · doi:10.1038/s41551-025-01420-w · Cited by 28
CRISPR/Cas9 and iPSC-Based Therapeutic Approaches in Alzheimer’s Disease
Raffaele, I., Cipriano, G. L., Anchesi, I., Oddo, S., & Silvestro, S. (2025) · Antioxidants · doi:10.3390/antiox14070781 · Cited by 30
Therapeutic Perspectives of Thermogenic Adipocytes in Obesity and Related Complications
Wang, C., & Wei, Y. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22137177 · Cited by 28
Cell therapy strategies for COVID-19: Current approaches and potential applications
Zaki, M. M., Lesha, E., Said, K., Kiaee, K., Robinson‐McCarthy, L. R., George, H., Hanna, A., Appleton, E., Liu, S., Ng, A. H. M., et al. (2021) · Science Advances · doi:10.1126/sciadv.abg5995 · Cited by 25
Induced Pluripotent Stem Cells as a Tool for Modeling Hematologic Disorders and as a Potential Source for Cell-Based Therapies
Pratumkaew, P., Issaragrisil, S., & Luanpitpong, S. (2021) · Cells · doi:10.3390/cells10113250 · Cited by 25
Emerging local immunomodulatory strategies to circumvent systemic immunosuppression in cell transplantation
Campa‐Carranza, J. N., Paez‐Mayorga, J., Chua, C. Y. X., Nichols, J. E., & Grattoni, A. (2022) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2022.2076834 · Cited by 29
Cardiac regeneration – Past advancements, current challenges, and future directions
Pezhouman, A., Nguyen, N. B., Kay, M., Kanjilal, B., Noshadi, I., & Ardehali, R. (2023) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2023.07.009 · Cited by 27
Progress and Challenges of Amniotic Fluid Derived Stem Cells in Therapy of Ischemic Heart Disease
Fang, Y., Wang, S. P. H., Chang, H., Yang, P.-J., Liu, P., & Liu, Y.-W. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010102 · Cited by 25
HLA‐E high /HLA‐G high /HLA‐II low Human iPSC‐Derived Cardiomyocytes Exhibit Low Immunogenicity for Heart Regeneration
Fang, Y., Wang, S. P. H., Liao, I., Tsai, K., Huang, P.-H., Yang, P.-J., Yen, C., Liu, P., Shan, Y., & Liu, Y.-W. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202301186 · Cited by 24
Unlocking the potential of iPSC-derived immune cells: engineering iNK and iT cells for cutting-edge immunotherapy
Fang, M., Allen, A. G., Luo, C., & Finn, J. D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1457629 · Cited by 26
Synthetic macromolecular switches for precision control of therapeutic cell functions
Teixeira, A. P., & Fussenegger, M. (2024) · Nature Reviews Bioengineering · doi:10.1038/s44222-024-00235-9 · Cited by 28
The Interface of Gene Editing with Regenerative Medicine
Farag, V., Devey, E. A., & Leong, K. W. (2024) · Engineering · doi:10.1016/j.eng.2024.10.019 · Cited by 30
A cloaked human stem-cell-derived neural graft capable of functional integration and immune evasion in rodent models
Pavan, C., Davidson, K. C., Payne, N. L., Frausin, S., Hunt, C. J., Moriarty, N., Rubio, M. Á. B., Elahi, Z., Quattrocchi, A. T., Abu-Bonsrah, K. D., et al. (2025) · Cell stem cell · doi:10.1016/j.stem.2025.03.008 · Cited by 27
Gene editing in dermatology: Harnessing CRISPR for the treatment of cutaneous disease
Baker, C. M., & Hayden, M. S. (2020) · F1000Research · doi:10.12688/f1000research.23185.1 · Cited by 26
Recent progress of animal transplantation studies for treating articular cartilage damage using pluripotent stem cells
Yamashita, A., & Tsumaki, N. (2021) · Development Growth & Differentiation · doi:10.1111/dgd.12706 · Cited by 24
Advances in Adoptive Cell Therapy Using Induced Pluripotent Stem Cell-Derived T Cells
Netsrithong, R., & Wattanapanitch, M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.759558 · Cited by 24
Cardiovascular Tissue Engineering and Regeneration: A Plead for Further Knowledge Convergence
Bouten, C. V. C., Cheng, C., Vermue, I. M., Gawlitta, D., & Passier, R. C. (2022) · Tissue Engineering Part A · doi:10.1089/ten.tea.2021.0231 · Cited by 27
Human stem cell derived beta-like cells engineered to present PD-L1 improve transplant survival in NOD mice carrying human HLA class I
Santini-González, J., Castro-Gutiérrez, R., Becker, M. W., Rancourt, C., Russ, H. A., & Phelps, E. A. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.989815 · Cited by 26
The potential for Treg-enhancing therapies in transplantation
Steiner, R., & Pilat, N. (2022) · Clinical & Experimental Immunology · doi:10.1093/cei/uxac118 · Cited by 25
CAR NK Cells: The Future Is Now
Raftery, M. J., Franzén, A. S., & Pecher, G. (2023) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-061521-082320 · Cited by 24
Barriers to Treg therapy in Europe: From production to regulation
Hennessy, C., Deptuła, M., Hester, J., & Issa, F. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1090721 · Cited by 25
Vascular implants – new aspects for in situ tissue engineering
Blume, C. A., Kraus, X., Heene, S., Loewner, S., Stanislawski, N., Cholewa, F., & Blume, H. (2022) · Engineering in Life Sciences · doi:10.1002/elsc.202100100 · Cited by 24
Programmable production of bioactive extracellular vesicles in vivo to treat myocardial infarction
Fu, S., Wang, Z., Huang, P., Li, G., Jian, N., Li, Z., Zu, G., Zhou, P., Wang, L., Leong, D. T., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-58260-0 · Cited by 24
Cell-Based Therapy for the Treatment of Glioblastoma: An Update from Preclinical to Clinical Studies
Attia, N., Mashal, M., Pemminati, S., Omole, A. E., Edmondson, C. K., Jones, W., Priyadarshini, P., Mughal, T., Aziz, P., Zenick, B., et al. (2021) · Cells · doi:10.3390/cells11010116 · Cited by 26
SIRPα engagement regulates ILC2 effector function and alleviates airway hyperreactivity via modulating energy metabolism
Sakano, Y., Sakano, K., Hurrell, B. P., Shafiei-Jahani, P., Kazemi, M. H., Li, X., Shen, S. M.-C., Barbers, R. G., & Akbari, O. (2024) · Cellular and Molecular Immunology · doi:10.1038/s41423-024-01208-z · Cited by 24
Current Landscape of iPSC Haplobanks
Escribá, R., Beksaç, M., Griscelli, A. B., Glover, J. C., Koskela, S., Latsoudis, H., Querol, S., & Álvarez-Palomo, B. (2024) · Stem Cell Reviews and Reports · doi:10.1007/s12015-024-10783-7 · Cited by 23
3D Bioprinting and Translation of Beta Cell Replacement Therapies for Type 1 Diabetes
Gurlin, R. E., Giraldo, J. A., & Latres, E. (2020) · Tissue Engineering Part B Reviews · doi:10.1089/ten.teb.2020.0192 · Cited by 23
Development of pluripotent stem cell‐based human tenocytes
Nakajima, T., & Ikeya, M. (2020) · Development Growth & Differentiation · doi:10.1111/dgd.12702 · Cited by 25
Engineered stem cells targeting multiple cell surface receptors in tumors
Kavari, S. L., & Shah, K. (2019) · Stem Cells · doi:10.1002/stem.3069 · Cited by 22
Glial progenitor cell-based repair of the dysmyelinated brain: Progression to the clinic
Goldman, S. A., Mariani, J. N., & Madsen, P. M. (2021) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2020.12.004 · Cited by 22
Therapeutic correction of hemophilia A by transplantation of hPSC-derived liver sinusoidal endothelial cell progenitors
Gage, B. K., Merlin, S., Olgasi, C., Follenzi, A., & Keller, G. M. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110621 · Cited by 24
Hypoimmunogenic human pluripotent stem cells are valid cell sources for cell therapeutics with normal self-renewal and multilineage differentiation capacity
Chen, Y., Zhou, Y., Zhou, Z., Fang, Y., Ma, L., Zhang, X., Xiong, J., & Liu, L. (2023) · Stem Cell Research & Therapy · doi:10.1186/s13287-022-03233-z · Cited by 22
A metabolic role for CD47 in pancreatic β cell insulin secretion and islet transplant outcomes
Ghimire, K., Kale, A., Li, J. S. Y., Julovi, S. M., O’Connell, P. J., Grey, S. T., Hawthorne, W. J., Gunton, J. E., & Rogers, N. M. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.add2387 · Cited by 22
Diminished expression of major histocompatibility complex facilitates the use of human induced pluripotent stem cells in monkey
Wang, X., Lu, M., Tian, X., Ren, Y., Li, Y., Xiang, M., & Chen, S. (2020) · Stem Cell Research & Therapy · doi:10.1186/s13287-020-01847-9 · Cited by 22
Versatility of Induced Pluripotent Stem Cells (iPSCs) for Improving the Knowledge on Musculoskeletal Diseases
Sanjurjo‐Rodríguez, C., Castro-Viñuelas, R., Piñeiro-Ramil, M., Rodríguez-Fernández, S., Fuentes-Boquete, I. M., Blanco, F. J., & Díaz‐Prado, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176124 · Cited by 22
CRISPR-Cas9-mediated disruption of B2M and CIITA genes eliminates HLA class I and II expression in human induced pluripotent stem cells (MUSIi001-A-2)
Thongsin, N., Suwanpitak, S., & Wattanapanitch, M. (2023) · Stem Cell Research · doi:10.1016/j.scr.2023.103138 · Cited by 21
Generation and optimization of off-the-shelf immunotherapeutics targeting TCR-Vβ2+ T cell malignancy
Ren, J., Liao, X., Lewis, J. M., Chang, J., Qu, R., Carlson, K. R., Foss, F. M., & Girardi, M. (2024) · Nature Communications · doi:10.1038/s41467-024-44786-2 · Cited by 23
iPS cell therapy 2.0: Preparing for next‐generation regenerative medicine
Hui, K. K., & Yamanaka, S. (2024) · BioEssays · doi:10.1002/bies.202400072 · Cited by 23
Large Animal Models for the Clinical Application of Human Induced Pluripotent Stem Cells
Cong, X., Zhang, S., Ellis, M. W., & Luo, J. (2019) · Stem Cells and Development · doi:10.1089/scd.2019.0136 · Cited by 21
Pluripotent Stem Cell-Based Therapeutics for Muscular Dystrophies
Selvaraj, S., Kyba, M., & Perlingeiro, R. C. R. (2019) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2019.07.004 · Cited by 23
Autologous iPSC- and MSC-derived chondrocyte implants for cartilage repair in a miniature pig model
Lee, M., Lin, E. C., Sivapatham, A., Leiferman, E. M., Jiao, H., Lu, Y., Nemke, B. W., Leiferman, M., Markel, M. D., & Li, W. (2025) · Stem Cell Research & Therapy · doi:10.1186/s13287-025-04215-7 · Cited by 21
Understanding and treating paediatric hearing impairment
Wrobel, C., Zafeiriou, M.-P., & Moser, T. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2020.103171 · Cited by 26
Possible NK cell-mediated immune responses against iPSC-derived cells in allogeneic transplantation settings
Masuda, K., & Kawamoto, H. (2021) · Inflammation and Regeneration · doi:10.1186/s41232-020-00150-7 · Cited by 18
Recent Progress of Research Regarding the Applications of Stem Cells for Treating Diabetes Mellitus
Zhou, Z., Zhu, X., Huang, H., Xu, Z., Jiang, J., Chen, B., & Zhu, H. (2022) · Stem Cells and Development · doi:10.1089/scd.2021.0083 · Cited by 21
[Retracted] Recent Advances in Cell and Functional Biomaterial Treatment for Spinal Cord Injury
Liu, T., Zhu, W., Zhang, X., He, C., Liu, X., Xin, Q., Chen, K., & Wang, H. (2022) · BioMed Research International · doi:10.1155/2022/5079153 · Cited by 20
Retracted
How can clinical safety and efficacy concerns in stem cell therapy for spinal cord injury be overcome?
Hejrati, N., Wong, R., Khazaei, M., & Fehlings, M. G. (2023) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2023.2245321 · Cited by 22
Engineering Strategies for Generating Hypoimmunogenic Cells with High Clinical and Commercial Value
Malik, N. N., Jenkins, A. M., Mellon, J., & Bailey, G. (2019) · Regenerative Medicine · doi:10.2217/rme-2019-0117 · Cited by 20
Natural Killer Cells Prevent the Formation of Teratomas Derived From Human Induced Pluripotent Stem Cells
Benabdallah, B., Désaulniers-Langevin, C., Colas, C., Li, Y.-Y., Rousseau, G., Guimond, J., Haddad, É., & Beauséjour, C. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02580 · Cited by 17
Non-immunogenic Induced Pluripotent Stem Cells, a Promising Way Forward for Allogenic Transplantations for Neurological Disorders
Frederiksen, H. R. S., Doehn, U., Tveden‐Nyborg, P., & Freude, K. (2021) · Frontiers in Genome Editing · doi:10.3389/fgeed.2020.623717 · Cited by 22
Recent advances in the induced pluripotent stem cell‐based skin regeneration
Choudhury, S., Surendran, N., & Das, A. (2021) · Wound Repair and Regeneration · doi:10.1111/wrr.12925 · Cited by 22
GMP-compliant iPS cell lines show widespread plasticity in a new set of differentiation workflows for cell replacement and cancer immunotherapy
Terheyden-Keighley, D., Hühne, M., Berger, T. G., Hiller, B., Martins, S., Gamerschlag, A., Sabour, D., Meffert, A., Kislat, A., Slotta, C., et al. (2024) · Stem Cells Translational Medicine · doi:10.1093/stcltm/szae047 · Cited by 19
Xenogeneic-free generation of vascular smooth muscle cells from human induced pluripotent stem cells for vascular tissue engineering
Luo, J., Lin, Y., Shi, X., Li, G., Kural, M. H., Anderson, C. W., Ellis, M. W., Riaz, M., Tellides, G., Niklason, L. E., et al. (2020) · Acta Biomaterialia · doi:10.1016/j.actbio.2020.10.042 · Cited by 19
Bioengineering the Cardiac Conduction System: Advances in Cellular, Gene, and Tissue Engineering for Heart Rhythm Regeneration
Naumova, N., & Iop, L. (2021) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2021.673477 · Cited by 19
Inhibition of complement activation by CD55 overexpression in human induced pluripotent stem cell derived kidney organoids
Gaykema, L., van Nieuwland, R. V., Dekkers, M. C., van Essen, M. V., Heidt, S., Zaldumbide, A., van den Berg, C. W., Rabelink, T., & van Kooten, C. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1058763 · Cited by 36
Complete correction of murine phenylketonuria by selection-enhanced hepatocyte transplantation
Vonada, A., Wakefield, L., Martinez, M., Harding, C. O., Grompe, M., & Tiyaboonchai, A. (2023) · Hepatology · doi:10.1097/hep.0000000000000631 · Cited by 19
Beneath the radar: immune-evasive cell sources for stroke therapy
Buil, B. A., Rentsch, N. H., Weber, R., Rickenbach, C., Halliday, S., Hotta, A., Tackenberg, C., & Rust, R. (2024) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2023.12.004 · Cited by 20
Cell-Based Therapies for Age-Related Macular Degeneration
Khateb, S., Jha, S., Bharti, K., & Banin, E. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-66014-7_11 · Cited by 21
A 3D-printed microdevice encapsulates vascularized islets composed of iPSC-derived β-like cells and microvascular fragments for type 1 diabetes treatment
Chen, S., Wang, W., Shen, L., Liu, H., Luo, J. C., Ren, Y., Cui, S., Ye, Y., Shi, G., Cheng, F., et al. (2024) · Biomaterials · doi:10.1016/j.biomaterials.2024.122947 · Cited by 19
Hypoimmune CD19 CAR T cells evade allorejection in patients with cancer and autoimmune disease
Hu, X., Beauchesne, P. R., Wang, C., Wong, A. W., Deuse, T., & Schrepfer, S. (2025) · Cell stem cell · doi:10.1016/j.stem.2025.07.009 · Cited by 20
Self-citation
HLA matching or CRISPR editing of HLA class I/II enables engraftment and effective function of allogeneic human regulatory T cell therapy in a humanized mouse transplantation model
McCallion, O., Du, W., Glaser, V., Milward, K. F., Short, S., Bilici, M., Cross, A. R., Stark, H. L., Franke, C., Kath, J., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-64945-3 · Cited by 22
Light control of RTK activity: from technology development to translational research
Leopold, A. V., & Verkhusha, V. V. (2020) · Chemical Science · doi:10.1039/d0sc03570j · Cited by 18
Intestinal organoids: roadmap to the clinic
Kasendra, M. J., Troutt, M. L., Broda, T. R., Bacon, W. C., Wang, T. C., Niland, J. C., & Helmrath, M. A. (2021) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00425.2020 · Cited by 18
Stem Cells as a Source of Pancreatic Cells for Production of 3D Bioprinted Bionic Pancreas in the Treatment of Type 1 Diabetes
Wszola, M., Nitarska, D., Cywoniuk, P., Gomółka, M., & Klak, M. (2021) · Cells · doi:10.3390/cells10061544 · Cited by 20

Authors: Deuse, T., Hu, X., Gravina, A., Wang, D., Tediashvili, G., De, C., Thayer, W. O., Wahl, A., Garcia, J. V., Reichenspurner, H., Davis, M. M., Lanier, L. L., & Schrepfer, S.
Affiliations: University of California, San Francisco (US)
Universität Hamburg (DE)
University of North Carolina at Chapel Hill (US)
Howard Hughes Medical Institute (US)
Corresponding author: Schrepfer, Sonja
ORCID: Deuse, Tobias
Hu, Xiaomeng
Gravina, Alessia
Wang, Dong
Tediashvili, Grigol
De, Chandrav
Wahl, Angela
Davis, Mark M.
Lanier, Lewis L.
Schrepfer, Sonja
Venue: Nature Biotechnology
Publisher: Springer Science and Business Media LLC
Published: 2019-02-18
Volume: 37
Issue: 3
Pages: 252-258
ISSN: 0733-222X (ISSN-L)
1087-0156
1546-1696
DOI: 10.1038/s41587-019-0016-3
PMC: PMC6419516
OpenAlex: W2911604931
Cited by: 758
References: 31
Citations by year: 2026: 98 · 2025: 102 · 2024: 102 · 2023: 113 · 2022: 94 · 2021: 97 · 2020: 106 · 2019: 46
FWCI: 28.36
Type: journal article
Language: en
Update notices: correction (2022-09-16)
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
www.springer.com/tdm (vor)
Locations: Nature Biotechnology (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
eScholarship (California Digital Library) (submittedVersion)
Funders: National Heart, Lung, and Blood Institute (R01HL140236)
National Institute of Mental Health (R01MH108179)
National Institute of Allergy and Infectious Diseases (R01AI068129, R01AI111899, R01AI123010, U19AI057229)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
Health Sciences › Medicine › Transplantation › Organ and Tissue Transplantation Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
Keywords: induced pluripotent stem cells, immune rejection, allogeneic transplantation, MHC mismatch, endothelial cells, smooth muscle cells, cardiomyocytes, immunosuppression-free transplantation
MeSH terms: Animals, Cell Differentiation, Graft Rejection, HLA Antigens, Humans, Transplantation, Homologous, Histocompatibility Antigens Class I, Myocytes, Cardiac, Mice, Induced Pluripotent Stem Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Hypoimmunogenic derivatives of induced pluripotent stem cells evade immune rejection in fully immunocompetent allogeneic recipients

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks